Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the role of the ectodysplasin A2 receptor as a biomarker and driver of ageing related to inflammation, and its potential therapeutic implications, but reports no new clinical findings.

This study found that patients with RASopathies have lower serum IgA and CD8 levels compared to controls, indicating a potential risk for developing autoimmune disorders.

This study developed a new measurement procedure using isotope dilution-liquid chromatography-tandem mass spectrometry for accurate quantification of DHEAS in human serum or plasma, demonstrating high selectivity, sensitivity, and low measurement uncertainty, making it suitable for routine standardization and clinical evaluation.

This study demonstrated that AIRE-deficient rats exhibit key symptoms of APECED, making them a relevant model for exploring potential treatments.

In a study on female SD rats, the authors found that RADA16-1 short-peptide nano-fiber gel scaffolds improved burn wound healing, hair follicle growth, hair growth length, and expression of bFGF and EGF compared to a NaCl control.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

This study found that treatment with ritlecitinib led to significant scalp hair regrowth in patients with alopecia areata at Weeks 24 and 48, with higher response rates observed in those receiving 50 mg compared to 30 mg doses.

This study identified a missense mutation in the rat Desmoglein 4 gene, causing abnormal hair shaft development in lanceolate hair mutant rats by disrupting a critical calcium binding site.

This study concluded that the combination of all-trans-retinoic acid and tocopherol-α is not recommended for treating del(5q) myelodysplastic syndromes due to low efficacy and high incidence of adverse effects.

In this study, researchers explored the use of a 2-deoxy-D-ribose sodium alginate hydrogel on mice with androgenic alopecia and found it resulted in similar hair regrowth to minoxidil, highlighting increased hair follicle density and angiogenesis.

This abstract discusses two types of hereditary vitamin D metabolism defects, VDDR I and VDDR II, and reports on their distinct characteristics and treatment responses, without presenting new clinical data.

This study reports that long-term treatment with ritlecitinib is generally well tolerated for up to approximately five years in patients aged 12 and older with alopecia areata, with the safety profile aligning with previous data from the ALLEGRO clinical trials.

In this study using a rat model, discontinuing dutasteride improved some relaxant responses but did not fully restore erectile function, indicating a potential time-dependent detriment of the drug.

Farudodstat may help treat alopecia areata by protecting hair follicles.

This study reports that a lower 2D:4D finger length ratio is significantly associated with higher disease activity and reduced spinal mobility in females with ankylosing spondylitis, but not in males.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

In this study, EDA-A2 transgenic mice exhibited multifocal myodegeneration dependent on XEDAR, suggesting a potential role for XEDAR in skeletal muscle homeostasis.

This study reported that ritlecitinib was prescribed to a diverse group of patients with severe alopecia areata in the first 10 months after FDA approval, indicating its potential role in AA management.

This study reports that among adults with severe alopecia areata taking ritlecitinib, 49% saw hair regrowth within 3 months, increasing to 82% after more than 6 months; treatment satisfaction also rose with longer duration, indicating sustained efficacy and improved quality of life over time.

Over 45% of patients with alopecia areata benefit from ritlecitinib, mostly within a year.

This study found a significant association between male breast cancers and exposure to finasteride and dutasteride, with an estimated additional case per 564 men taking these drugs.

Farudodstat may effectively treat alopecia areata without harming hair follicles.

This report describes a 17-year-old woman who experienced severe anagen effluvium after DRESS syndrome but achieved full recovery in two months with topical minoxidil.

In this study, the authors developed a novel PROTAC named dAR-6–1, which demonstrated superior hair regeneration in an AGA mouse model compared to minoxidil, highlighting its promise as a therapy due to potent AR degradation and excellent skin permeability.

DNCB is highly effective for treating alopecia areata with minimal long-term side effects.

In this case report, researchers described a two-year-old girl with Vitamin D dependent rickets Type II, noting elevated 1,25-dihydroxyvitamin D3 and alopecia, and observed limited treatment response likely due to poor compliance.

This source reports that trastuzumab deruxtecan improves outcomes in HER2-positive and HER2-low metastatic breast cancer, emphasizing the need for careful adverse event monitoring, particularly for interstitial lung disease, and managing emetic risk to maximize benefits.

This study found that dimethylarsinic acid significantly accelerates skin tumor development in hair follicle-targeted K6/ODC transgenic mice.

In this retrospective cohort study, researchers reported that 11.5% of patients with DRESS developed significant long-term autoimmune or renal sequelae, with age influencing the type of sequelae observed.